NCT02154022: Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 2 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be currently enrolled in an IRB approved NIH Intramural Research Program (IRP) clinical trial

Comments are closed.

Up ↑